Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.59 |
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387246 | 0.88 | NR4A2 (0.77) | F2NR4A2MAOBPARP10SMPD1 | |
| SCHEMBL4638741 | 0.87 | NR4A2 (0.76) | F2NR4A2MAOBPARP10MAOA | |
| SCHEMBL4639668 | 0.87 | MAOB (0.76) | F2NR4A2MAOBPARP10MAOA | |
| SCHEMBL4638697 | 0.87 | MAOB (0.74) | F2NR4A2MAOBPARP10MAOA | |
| SCHEMBL4640232 | 0.87 | NR4A2 (0.76) | F2NR4A2MAOBPARP10MAOA | |
| SCHEMBL7451063 | 0.87 | NR4A2 (0.70) | F2NR4A2MAOBPARP10SMPD1 | |
| Hydrochloric Acid SCHEMBL27603151 | 0.86 | NR4A2 (0.74) | F2NR4A2MAOBPARP10SMPD1 | |
| SCHEMBL4638961 | 0.86 | MRGPRX4 (0.59) | F2NR4A2MAOBPARP10MAOA | |
| SCHEMBL7438620 | 0.85 | SMPD1 (0.71) | F2NR4A2MAOBPARP10MAOA | |
| SCHEMBL7444275 | 0.85 | NR4A2 (0.60) | F2NR4A2MAOBPARP10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0749415-B1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | UNIV NEWCASTLE VENTURES LTD (GB) | 1999-09-08 | — | — | EP | claimed |
| US-5756510-A | POTENTIATE EFFECTS OF CYTOTOXIC DRUGS OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-26 | — | — | US | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017042634-A2 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE | DEL MAR PHARMACEUTICALS (CA) | 2017-03-16 | — | — | WO | disclosed |
| US-6316455-B1 | Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-11-13 | — | — | US | disclosed |
| US-6015827-A | Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy | NEWCASTLE UNIVERSITY VENTURES LIMITED | 2000-01-18 | — | — | US | disclosed |
| EP-0749415-B1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | UNIV NEWCASTLE VENTURES LTD (GB) | 1999-09-08 | — | — | EP | disclosed |
| US-5756510-A | POTENTIATE EFFECTS OF CYTOTOXIC DRUGS OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-26 | — | — | US | disclosed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | F2 4756/4885NR4A2 3588/4885MAOB 4776/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | F2 4756/4885NR4A2 3588/4885MAOB 4776/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | F2 4756/4885NR4A2 3588/4885MAOB 4776/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | F2 1433/4885NR4A2 3542/4885MAOB 2815/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | F2 4756/4885NR4A2 3588/4885MAOB 4776/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | F2 3652/4885NR4A2 3719/4885MAOB 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.